ArticleBiomaterials2014
The effect of multistage nanovector targeting of VEGFR2 positive tumor endothelia on cell adhesion and local payload accumulation.
Article in Biomaterials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer.Scientific reports · 2021Article
- Development and Characterization of PLGA-Based Multistage Delivery System for Enhanced Payload Delivery to Targeted Vascular Endothelium.Macromolecular bioscience · 2021Article
- Manipulation of immune‒vascular crosstalk: new strategies towards cancer treatment.Acta pharmaceutica Sinica. B · 2020Review
- Cell membrane protein functionalization of nanoparticles as a new tumor-targeting strategy.Clinical and translational medicine · 2019Review
- Trends towards Biomimicry in Theranostics.Nanomaterials (Basel, Switzerland) · 2018Review
- Inflammation and Cancer: In Medio Stat Nano.Current medicinal chemistry · 2018Review
- Ultrasound molecular imaging of breast cancer in MCF-7 orthotopic mice using gold nanoshelled poly(lactic-co-glycolic acid) nanocapsules: a novel dual-targeted ultrasound contrast agent.International journal of nanomedicine · 2018Article
- Biomimetic carriers mimicking leukocyte plasma membrane to increase tumor vasculature permeability.Scientific reports · 2016Article
- The Emerging Role of Nanotechnology in Cell and Organ Transplantation.Transplantation · 2016Review
- Cell source determines the immunological impact of biomimetic nanoparticles.Biomaterials · 2016Article
- The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery.Nanomedicine (London, England) · 2016Review
- Multistage vector (MSV) therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- Multistage Nanovectors Enhance the Delivery of Free and Encapsulated Drugs.Current drug targets · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 2 countries.
Funding
Abstract
Nanovectors are a viable solution to the formulation of poorly soluble anticancer drugs. Their bioaccumulation in the tumor parenchyma is mainly achieved exploiting the enhanced permeability and retention (EPR) effect of the leaky neovasculature. In this paper we demonstrate that multistage nanovectors (MSV) exhibit rapid tumoritropic homing independent of EPR, relying on particle geometry and surface adhesion. By studying endothelial cells overexpressing vascular endothelial growth factor receptor-2 (VEGFR2), we developed MSV able to preferentially target VEGFR2 expressing tumor-associated vessels. Static and dynamic targeting revealed that MSV conjugated with anti-VEGFR2 antibodies displayed greater than a 4-fold increase in targeting efficiency towards VEGFR2 expressing cells while exhibiting minimal adherence to control cells. Additionally, VEGFR2 conjugation bestowed MSV with a significant increase in breast tumor targeting and in the delivery of a model payload while decreasing their accumulation in the liver. Surface functionalization with an anti-VEGFR2 antibody provided enhanced affinity towards the tumor vascular endothelium, which promoted enhanced adhesion and tumoritropic accumulation of a reporter molecule released by the MSV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.